An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

ClinicalTrials.gov ID: NCT07365332

Public ClinicalTrials.gov record NCT07365332. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 9, 2026, 6:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension (PAH)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.

Study identification

NCT ID: NCT07365332
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Inhibikase Therapeutics; Industry
Enrollment: 486 participants

Conditions and interventions

Conditions

Pulmonary Arterial Hypertension

Interventions

IKT-001 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 22, 2026
Primary completion: May 31, 2029
Completion: Nov 30, 2029
Last update posted: Sep 1, 2026

2026 – 2029

United States locations

U.S. sites: 15
U.S. states: 12
U.S. cities: 15

Facility	City	State	ZIP	Site status
Arizona Pulmonary Specialists, LTD	Scottsdale	Arizona	85258	Recruiting
Cedars Sinai	Beverly Hills	California	90211	Recruiting
Jeffrey S. Sager, MD Medical Corporation	Santa Barbara	California	93105	Recruiting
Lundquist at Harbor UCLA	Torrance	California	90502	Recruiting
University of Colorado Anschutz Medical Campus	Aurora	Colorado	80045	Recruiting
University of Kansas Medical Center	Kansas City	Kansas	66103	Recruiting
Norton Healthcare	Louisville	Kentucky	40202	Recruiting
Tufts Medical Center	Boston	Massachusetts	02111	Recruiting
Washington University School of Medicine	St Louis	Missouri	63110	Recruiting
NYU Langone Health	New York	New York	10016	Recruiting
Westchester Medical Center	Valhalla	New York	10595	Recruiting
Duke University	Durham	North Carolina	27710	Recruiting
University of Cincinnati	Cincinnati	Ohio	45267	Recruiting
Vanderbilt University Medical Center	Nashville	Tennessee	37232-7610	Recruiting
UT Southwestern Medical Center	Dallas	Texas	75390	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07365332, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 1, 2026 · Synced Sep 9, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07365332 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →